Affinity-Purified Respiratory Syncytial Virus Antibodies from Intravenous Immunoglobulin Exert Potent Antibody-Dependent Cellular Cytotoxicity
Open Access
- 19 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e69390
Abstract
Mixed infections are one of the major therapeutic challenges, as the current strategies have had limited success. One of the most common and widespread conditions of mixed infection is respiratory syncytial virus-mediated pathology of the respiratory tract in children. There is a dire need for the development of novel therapeutic approaches during mixed infections. Therapeutic intravenous immunoglobulin preparations, obtained from plasma pools of healthy donors have been used in immune deficiencies. This study was thus designed to characterize the functional efficacy of RSV-specific antibodies in IVIg. To explore the functional ability of these affinity-purified RSV-specific antibodies, the antibody-dependent and complement dependent cytotoxicity was determined using peripheral cells of healthy donors. This study demonstrates the existence of highly potent RSV-specific antibodies in IVIg preparations and provides the basis for the use of IVIg as broad-spectrum protective shield to RSV-infected children during mixed infections.Keywords
This publication has 26 references indexed in Scilit:
- Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c MicePLOS ONE, 2012
- The Secreted G Protein of Human Respiratory Syncytial Virus Antagonizes Antibody-Mediated Restriction of Replication Involving Macrophages and ComplementJournal of Virology, 2012
- Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B StrainsViral Immunology, 2012
- Tick-Borne Encephalitis Virus-Neutralizing Antibodies in Different Immunoglobulin PreparationsClinical and Vaccine Immunology, 2012
- Intravenous immunoglobulin therapy in rheumatic diseasesNature Reviews Rheumatology, 2011
- Advances in the assessment and control of the effector functions of therapeutic antibodiesNature Reviews Drug Discovery, 2011
- In vitro comparison of the complement‐scavenging capacity of different intravenous immunoglobulin preparationsVox Sanguinis, 2009
- Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in miceJournal of General Virology, 2009
- Bronchiolitis in infantsCurrent Opinion in Pediatrics, 2001
- Comparison of Antibody Concentrations and Protective Activity of Respiratory Syncytial Virus Immune Globulin and Conventional Immune GlobulinThe Journal of Infectious Diseases, 1994